Floatz logo

Azacitidine

Safety and Efficacy

Sun Yat-sen UniversitySmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

5 Active assets in the Safety and Efficacy cohort.

Asset / SponsorPhaseRating
Tucidinostat
Sun Yat-sen University
Phase 2BB
L-Dep
Sun Yat-sen University
Phase 2CCC
Tisagenlecleucel
The First Affiliated Hospital of Soochow University
Phase 1/2CCC
Jwcar129
The First Affiliated Hospital of Soochow University
Phase 1CC
Clozapine
Ruijin Hospital
Early Phase 1C
Car-Nk Cells Targeting Nkg2D Ligands
Hangzhou Cheetah Cell Therapeutics Co., Ltd
N/AD

Same molecule, other indications

Azacitidine is also rated in:

acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Dormant
BBB
Indicative ·
73 / 100
View asset →
acute erythroid leukemiaDormant
BB
Indicative ·
71 / 100
View asset →
non-small cell lung carcinomaDormant
BB
Indicative ·
71 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →